Study on the correlation between the expression amplification of human epidermal growth factor receptor 2 gene and prognosis in endometrial cancer tissues based on molecular typing
10.3760/cma.j.cn115455-20230803-00070
- VernacularTitle:基于分子分型子宫内膜癌组织中人表皮生长因子受体2基因表达扩增与预后相关性研究
- Author:
Leilei WANG
1
;
Xiuying WANG
;
Lu HAN
;
Chenggong ZHU
;
Xianting GUO
Author Information
1. 大连市妇女儿童医疗中心（集团）妇瘤科，大连 116037
- Publication Type:Journal Article
- Keywords:
Endometrial neoplasms;
Genes, p53;
Genes, human epidermal growth factor receptor 2;
Prognosis;
Targeted therapy
- From:
Chinese Journal of Postgraduates of Medicine
2025;48(2):106-111
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the human epidermal growth factor receptor 2 gene(HER2) expression amplification in endometrial cancer (EC) with different p53 expression patterns based on molecular typing, as well as their correlation and impact on prognosis.Methods:A retrospective analysis was conducted on 282 patients with EC who underwent surgical treatment at Dalian Women and Children′s Medical Center (Group) from January 2016 to December 2018 with complete clinical and pathological data. Immunohistochemistry and fluorescence in situ hybridization were used to detect the amplification of HER2 gene expression in paraffin- embedded tumor tissue of patients after surgery and confirmed the expression of p53. The clinical data were collected and tracked follow-up.Results:There were significant differences between HER2-positive patients and HER2-negative patients in the age of onset, pathological types of tumor tissue, depth of muscle infiltration, and tumor differentiation ( P< 0.05). The 5-year survival rate and 5-year progression-free survival rate of HER2-positive patients were lower than those of HER2-negative patients (45.45% vs. 95.16%, 45.45% vs. 95.11%), and there were statistical differences ( P<0.01). The positive expression of HER2 in EC tissues was positively correlated with p53 mutant expression ( r = 0.409, P<0.01). Among p53 wild-type EC patients, the 5-year survival rate was 98.4% for HER2-negative patients and 100.00% for HER2-positive patients. In the patients with p53 mutant EC, 58.05% and 37.50%, respectively, there was a statistical difference ( P<0.01). The 5-year progression-free survival rates were 97.50%, 100.00%, 60.20%, and 37.50%, respectively, and there was a statistical difference ( P<0.01). Conclusions:There is a significant positive correlation between HER2 positive overexpression and p53 mutant expression in EC tissue, and there is an inherent synergy between the two expressions. HER2 positive over expression is a key factor for poor prognosis in EC patients. Patients with HER2- positive over expression and p53 mutant expression have poorer 5-year overall survival and progression- free survival compared to other groups.
